A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (NCT06706817)
A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE)
🩺 Plain-English Summary (8th-Grade Level)
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Who can join: Review the eligibility criteria below.
Location: Research Site — Newport Beach, California
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- Research Site — Newport Beach, California
- Research Site — Chicago, Illinois
- Research Site — Chestnut Hill, Massachusetts
- Research Site — Columbia, Missouri
- Research Site — Plovdiv,
- Research Site — Sofia,
- Research Site — Sofia,
- Research Site — Hamilton, Ontario
- Research Site — Québec, Quebec
- Research Site — Québec, Quebec
- Research Site — Le Kremlin-Bicêtre,
- Research Site — Marseille,
- Research Site — Nantes,
- Research Site — Pierre-Bénite,
- Research Site — Poitiers,
- Research Site — Toulouse,
- Research Site — Marburg,
- Research Site — Tübingen,
- Research Site — Villingen-Schwenningen,
- Research Site — Wiesbaden,
- Research Site — Budapest,
- Research Site — Budapest,
- Research Site — Nyíregyháza,
- Research Site — Pécs,
- Research Site — Bologna,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Rhinosinusitis With Nasal Polyps
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps — Arcadia, California
- An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps — La Mesa, California
- Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS — London, Ontario
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps — Birmingham, Alabama
- Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis — London, Ontario
Explore by condition: All Chronic Rhinosinusitis With Nasal Polyps clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.